EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia

Albert Wiegman iD, Susanne Greber-Platzer iD, Shazia Ali, M Doortje Reijman iD, Eliot A Brinton iD, Min-Ji Charng iD, Shubha Srinivasan, Carissa Baker-Smith iD, Seth Baum iD, Julie A Brothers, Jacob Hartz, Patrick M Moriarty iD und 6 weitere

Circulation · 30.01.2024 · 149 (5) · 343-353

DOI: 10.1161/circulationaha.123.065529 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation, erschienen am 30.01.2024. Verfasst von Albert Wiegman und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics, Amsterdam University Medical Centers, Location University of Amsterdam, The Netherlands (A.W., M.D.R.). Hauptthemen laut MEDLINE: Homozygous Familial Hypercholesterolemia, Hyperlipoproteinemia Type II, Anticholesteremic Agents, Antibodies, Monoclonal. Die Arbeit wurde bisher 95-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by severely elevated low-density lipoprotein cholesterol (LDL-C) levels due to profoundly defective LDL receptor (LDLR) function. Given that severely elevated LDL-C starts in utero, atherosclerosis often presents during childhood or adolescence, creating a largely unmet need for aggressive LDLR-independent lipid-lowering therapies in young patients with HoFH. Here we present the first evaluation of the efficacy and safety of evinacumab, a novel LDLR-independent lipid-lowering therapy, in pediatric patients with HoFH from parts A and B of a 3-part study. METHODS: The phase 3, part B, open-label study treated 14 patients 5 to 11 years of age with genetically proven HoFH (true homozygotes and compound heterozygotes) with LDL-C >130 mg/dL, despite optimized lipid-lowering therapy (including LDLR-independent apheresis and lomitapide), with intravenous evinacumab 15 mg/kg every 4 weeks. RESULTS: Evinacumab treatment rapidly and durably (through week 24) decreased LDL-C with profound reduction in the first week, with a mean (SE) LDL-C reduction of −48.3% (10.4%) from baseline to week 24. ApoB (mean [SE], –41.3% [9.0%]), non–high-density lipoprotein cholesterol (–48.9% [9.8%]), and total cholesterol (–49.1% [8.1%]) were similarly decreased. Treatment-emergent adverse events were reported in 10 (71.4%) patients; however, only 2 (14.3%) reported events that were considered to be treatment-related (nausea and abdominal pain). One serious treatment-emergent adverse event of tonsillitis occurred (n=1), but this was not considered treatment-related. CONCLUSIONS: Evinacumab constitutes a new treatment for pediatric patients with HoFH and inadequately controlled LDL-C despite optimized lipid-lowering therapy, lowering LDL-C levels by nearly half in these extremely high-risk and difficult-to-treat individuals. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04233918.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Homozygous Familial HypercholesterolemiaHyperlipoproteinemia Type IIAnticholesteremic AgentsAntibodies, MonoclonalAdolescentHumansChildCholesterol, LDLHomozygote

Stichwörter der Autor:innen

angiopoietin-like protein 3atherosclerosisevinacumabhomozygous familial hypercholesterolemialipidslipoproteinpediatrics

Substanzen

Cholesterol, LDLevinacumabAnticholesteremic AgentsAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Paediatrics, Amsterdam University Medical Centers, Location University of Amsterdam, The Netherlands (A.W., M.D.R.).
  • Department of Pediatrics and Adolescent Medicine, Division of Pediatric Pulmonology, Allergology and Endocrinology, Medical University of Vienna, Austria (S.G.-P.).
  • Regeneron Pharmaceuticals, Inc, Tarrytown, NY (S.A., J.M., S.B., P.B., R.T.G., B.H., R.P.).
  • Utah Lipid Center, Salt Lake City (E.A.B.).
  • Division of Cardiology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan (M.-J.C.).
  • Institute of Endocrinology and Diabetes, Children's Hospital at Westmead, Sydney, Australia (S.S.).

ORCID-Profile: Albert Wiegman, Susanne Greber-Platzer, M Doortje Reijman, Eliot A Brinton, Min-Ji Charng, Carissa Baker-Smith, Seth Baum, Patrick M Moriarty, Sébastien Bihorel, Poulabi Banerjee, Richard T George, Robert Pordy

Zitieren

APA

Wiegman, A., Greber-Platzer, S., Ali, S., Reijman, M. D., Brinton, E. A., Charng, M. J., Srinivasan, S., Baker-Smith, C., Baum, S., Brothers, J. A., Hartz, J., Moriarty, P. M., Mendell, J., Bihorel, S., Banerjee, P., George, R. T., Hirshberg, B., & Pordy, R. (2024). Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia. Circulation, 149(5), 343-353. https://doi.org/10.1161/circulationaha.123.065529

Vancouver

Wiegman A, Greber-Platzer S, Ali S, Reijman MD, Brinton EA, Charng MJ, et al. Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia. Circulation. 2024;149(5):343-353. doi:10.1161/circulationaha.123.065529

BibTeX
@article{Wiegman2024,
  author = {Wiegman, Albert and Greber-Platzer, Susanne and Ali, Shazia and Reijman, M Doortje and Brinton, Eliot A and Charng, Min-Ji and Srinivasan, Shubha and Baker-Smith, Carissa and Baum, Seth and Brothers, Julie A and Hartz, Jacob and Moriarty, Patrick M and Mendell, Jeanne and Bihorel, Sébastien and Banerjee, Poulabi and George, Richard T and Hirshberg, Boaz and Pordy, Robert},
  title = {Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia},
  journal = {Circulation},
  year = {2024},
  volume = {149},
  number = {5},
  pages = {343--353},
  doi = {10.1161/circulationaha.123.065529}
}
Kostenlos starten →